# Clinical trial results:
# A Phase 3, Randomized, Double-blind Trial to Evaluate the Safety of a 20-Valent Pneumococcal Conjugate Vaccine in Healthy Infants

## Summary

| | |
|---|---|
| EudraCT number | 2019-003307-35 |
| Trial protocol | HU DE GR FI CZ |
| Global end of trial date | 31 August 2022 |

### Results information

| | |
|---|---|
| Result version number | v1 (current) |
| This version publication date | 10 February 2023 |
| First version publication date | 10 February 2023 |

## Trial information

### Trial identification

| | |
|---|---|
| Sponsor protocol code | B7471013 |

### Additional study identifiers

| | |
|---|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT04379713 |
| WHO universal trial number (UTN) | - |

Notes:

### Sponsors

| | |
|---|---|
| Sponsor organisation name | Pfizer Inc. |
| Sponsor organisation address | 235 E 42nd Street, New York, United States, NY 10017 |
| Public contact | Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 18007181021, ClinicalTrials.gov_Inquiries@pfizer.com |
| Scientific contact | Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 18007181021, ClinicalTrials.gov_Inquiries@pfizer.com |

Notes:

### Paediatric regulatory details

| | |
|---|---|
| Is trial part of an agreed paediatric investigation plan (PIP) | Yes |
| EMA paediatric investigation plan number(s) | EMEA-002330-PIP01-18 |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | Yes |

Notes:

## Results analysis stage

| | |
|---|---|
| Analysis stage | Final |
| Date of interim/final analysis | 09 September 2022 |
| Is this the analysis of the primary completion data? | No |

| | |
|---|---|
| Global end of trial reached? | Yes |
| Global end of trial date | 31 August 2022 |
| Was the trial ended prematurely? | No |

Notes:

## General information about the trial

Main objective of the trial:

To describe the safety profile of 20-Valent Pneumococcal Conjugate Vaccine (20vPnC).

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Council for Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

| | |
|---|---|
| Actual start date of recruitment | 21 May 2020 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

## Population of trial subjects

### Subjects enrolled per country

| | |
|---|---|
| Country: Number of subjects enrolled | Argentina: 79 |
| Country: Number of subjects enrolled | Canada: 189 |
| Country: Number of subjects enrolled | Chile: 30 |
| Country: Number of subjects enrolled | Czechia: 29 |
| Country: Number of subjects enrolled | Germany: 49 |
| Country: Number of subjects enrolled | Spain: 320 |
| Country: Number of subjects enrolled | Finland: 17 |
| Country: Number of subjects enrolled | Greece: 31 |
| Country: Number of subjects enrolled | Hungary: 262 |
| Country: Number of subjects enrolled | Puerto Rico: 19 |
| Country: Number of subjects enrolled | United States: 478 |
| Worldwide total number of subjects | 1503 |
| EEA total number of subjects | 708 |

Notes:

### Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |

| | |
|---|---|
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 1503 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 0 |
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

A total of 1511 subjects were enrolled and randomised in the study. 7 subjects did not receive any vaccine. 1 subject who was randomised to 13vPnC group received 20vPnC vaccination at Dose 1 which was not as per randomisation. Hence, data of these subjects were excluded from analysis.

### Period 1

| | |
|---|---|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator |

### Arms

| | |
|---|---|
| Are arms mutually exclusive? | Yes |
| **Arm title** | 20vPnC |

Arm description:

Infants 42 to 98 days of age were enrolled to receive 4 doses of 0.5 millilitre (mL) 20-valent Pneumococcal Conjugate Vaccine (20vPnC) intramuscularly (IM). The first dose was given at Day 1, with the second and third doses given at 42-63 day intervals. Dose 4 was administered between 12 to 15 months of age. Subjects were followed up to 6 months after last dose.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | 20-Valent Pneumococcal Conjugate Vaccine |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received 0.5 mL dose of 20vPnC intramuscularly on Visits 1, 2, 3, and 5 with Dose 1, 2, 3, and 4, respectively.

| | |
|---|---|
| **Arm title** | 13vPnC |

Arm description:

Infants 42 to 98 days of age were enrolled to receive 4 doses of 0.5 mL 13-valent Pneumococcal Conjugate Vaccine (13vPnC) intramuscularly. The first dose was given at Day 1, with the second and third doses given at 42-63 day intervals. Dose 4 was administered between 12 to 15 months of age. Subjects were followed up to 6 months after last dose.

| | |
|---|---|
| Arm type | Active comparator |
| Investigational medicinal product name | 13-Valent Pneumococcal Conjugate Vaccine |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received 0.5 mL dose of 13vPnC intramuscularly on Visits 1, 2, 3, and 5 with Dose 1, 2, 3, and 4, respectively.

| **Number of subjects in period 1** | 20vPnC | 13vPnC |
|---|---|---|
| Started | 1000 | 503 |
| Dose 1 (Vaccination 1) | 1000 | 503 |
| Dose 2 | 972 | 491 |
| Dose 3 | 964 | 482 |
| Dose 4 | 923 | 461 |
| Completed | 910 | 450 |
| Not completed | 90 | 53 |
| Physician decision | 1 | - |
| Adverse Event | 2 | - |
| No longer meets eligibility criteria | 14 | 11 |
| Lost to follow-up | 31 | 21 |
| Withdrawal by parent/guardian | 31 | 15 |
| Protocol deviation | 11 | 6 |

## Baseline characteristics

| Reporting groups | |
|---|---|
| Reporting group title | 20vPnC |
| Reporting group description: | |
| Infants 42 to 98 days of age were enrolled to receive 4 doses of 0.5 millilitre (mL) 20-valent Pneumococcal Conjugate Vaccine (20vPnC) intramuscularly (IM). The first dose was given at Day 1, with the second and third doses given at 42-63 day intervals. Dose 4 was administered between 12 to 15 months of age. Subjects were followed up to 6 months after last dose. | |
| Reporting group title | 13vPnC |
| Reporting group description: | |
| Infants 42 to 98 days of age were enrolled to receive 4 doses of 0.5 mL 13-valent Pneumococcal Conjugate Vaccine (13vPnC) intramuscularly. The first dose was given at Day 1, with the second and third doses given at 42-63 day intervals. Dose 4 was administered between 12 to 15 months of age. Subjects were followed up to 6 months after last dose. | |

| Reporting group values | 20vPnC | 13vPnC | Total |
|---|---|---|---|
| Number of subjects | 1000 | 503 | 1503 |
| Age Categorical<br>Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 1000 | 503 | 1503 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 0 | 0 | 0 |
| From 65-84 years | 0 | 0 | 0 |
| 85 years and over | 0 | 0 | 0 |
| Age Continuous<br>Units: days | | | |
| arithmetic mean | 64.6 | 65.0 | |
| standard deviation | ± 8.51 | ± 8.95 | - |
| Gender Categorical<br>Units: Subjects | | | |
| Female | 483 | 259 | 742 |
| Male | 517 | 244 | 761 |
| Race<br>Units: Subjects | | | |
| White | 868 | 445 | 1313 |
| Black or African American | 55 | 15 | 70 |
| Asian | 21 | 10 | 31 |
| American Indian or Alaskan native | 4 | 1 | 5 |
| Native Hawaiian or other Pacific Islander | 2 | 2 | 4 |
| Multiracial | 35 | 21 | 56 |
| Not reported | 15 | 9 | 24 |
| Ethnicity<br>Units: Subjects | | | |

| | | | |
|---|---|---|---|
| Hispanic/Latino | 367 | 193 | 560 |
| Non-Hispanic/non-Latino | 621 | 303 | 924 |
| Not reported | 12 | 7 | 19 |

## End points

### End points reporting groups

| Reporting group title | 20vPnC |
|---|---|

Reporting group description:

Infants 42 to 98 days of age were enrolled to receive 4 doses of 0.5 millilitre (mL) 20-valent Pneumococcal Conjugate Vaccine (20vPnC) intramuscularly (IM). The first dose was given at Day 1, with the second and third doses given at 42-63 day intervals. Dose 4 was administered between 12 to 15 months of age. Subjects were followed up to 6 months after last dose.

| Reporting group title | 13vPnC |
|---|---|

Reporting group description:

Infants 42 to 98 days of age were enrolled to receive 4 doses of 0.5 mL 13-valent Pneumococcal Conjugate Vaccine (13vPnC) intramuscularly. The first dose was given at Day 1, with the second and third doses given at 42-63 day intervals. Dose 4 was administered between 12 to 15 months of age. Subjects were followed up to 6 months after last dose.

### Primary: Percentage of Subjects With Local Reactions Within 7 Days After Dose 1

| End point title | Percentage of Subjects With Local Reactions Within 7 Days After Dose 1[1] |
|---|---|

End point description:

Local reactions included pain at injection site, redness and swelling. Redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit =0.5 centimeter (cm). Pain at injection site was graded as mild: hurts if gently touched; moderate: hurts if gently touched with crying; severe: limited limb movement. Redness and swelling were graded as mild: greater than (>) 0.0 to 2.0 cm; moderate >2.0 to 7.0 cm; and severe: >7.0 cm. Safety population included all the subjects who received at least 1 dose of the investigational product (IP) with safety follow up after any dose. Here, 'Number of Subjects Analysed' = number of subjects with any electronic diary (e-diary) data reported after Dose 1.

| End point type | Primary |
|---|---|

End point timeframe:

Within 7 Days after Dose 1

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive data was planned to be analysed for this endpoint.

| End point values | 20vPnC | 13vPnC | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 992 | 498 | | |
| Units: Percentage of subjects | | | | |
| number (confidence interval 95%) | | | | |
| Redness: Mild | 18.0 (15.7 to 20.6) | 16.5 (13.3 to 20.0) | | |
| Redness: Moderate | 3.7 (2.6 to 5.1) | 3.0 (1.7 to 4.9) | | |
| Redness: Severe | 0 (0.0 to 0.4) | 0 (0.0 to 0.7) | | |
| Swelling: Mild | 13.8 (11.7 to 16.1) | 11.2 (8.6 to 14.4) | | |
| Swelling: Moderate | 6.1 (4.7 to 7.8) | 5.4 (3.6 to 7.8) | | |
| Swelling: Severe | 0 (0.0 to 0.4) | 0 (0.0 to 0.7) | | |
| Pain at injection site: Mild | 24.8 (22.1 to 27.6) | 25.3 (21.5 to 29.4) | | |
| Pain at injection site: Moderate | 15.5 (13.3 to 17.9) | 16.7 (13.5 to 20.2) | | |
| Pain at injection site: Severe | 0.2 (0.0 to 0.7) | 0 (0.0 to 0.7) | | |

## Statistical analyses

No statistical analyses for this end point

## Primary: Percentage of Subjects With Local Reactions Within 7 Days After Dose 2

| End point title | Percentage of Subjects With Local Reactions Within 7 Days After Dose 2[2] |
|---|---|

End point description:

Local reactions included pain at injection site, redness and swelling. Redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit =0.5 cm. Pain at injection site was graded as mild: hurts if gently touched; moderate: hurts if gently touched with crying; severe: limited limb movement. Redness and swelling were graded as mild: >0.0 to 2.0 cm; moderate >2.0 to 7.0 cm; and severe: >7.0 cm. Safety population included all the subjects who received at least 1 dose of the investigational product with safety follow up after any dose. Here, 'Number of Subjects Analysed' = number of subjects with any e-diary data reported after Dose 2.

| End point type | Primary |
|---|---|

End point timeframe:

Within 7 Days after Dose 2

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive data was planned to be analysed for this endpoint.

| End point values | 20vPnC | 13vPnC | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 952 | 485 | | |
| Units: Percentage of subjects | | | | |
| number (confidence interval 95%) | | | | |
| Redness: Mild | 20.4 (17.9 to 23.1) | 19.4 (16.0 to 23.2) | | |
| Redness: Moderate | 3.2 (2.1 to 4.5) | 3.9 (2.4 to 6.1) | | |
| Redness: Severe | 0 (0.0 to 0.4) | 0 (0.0 to 0.8) | | |
| Swelling: Mild | 13.4 (11.3 to 15.8) | 13.4 (10.5 to 16.8) | | |
| Swelling: Moderate | 4.4 (3.2 to 5.9) | 5.6 (3.7 to 8.0) | | |
| Swelling: Severe | 0 (0.0 to 0.4) | 0 (0.0 to 0.8) | | |
| Pain at the injection site: Mild | 20.8 (18.3 to 23.5) | 20.2 (16.7 to 24.1) | | |
| Pain at the injection site: Moderate | 10.7 (8.8 to 12.9) | 11.8 (9.0 to 15.0) | | |
| Pain at the injection site: Severe | 0.7 (0.3 to 1.5) | 0.8 (0.2 to 2.1) | | |

## Statistical analyses

No statistical analyses for this end point

## Primary: Percentage of Subjects With Local Reactions Within 7 Days After Dose 3

| End point title | Percentage of Subjects With Local Reactions Within 7 Days After Dose 3[3] |
|---|---|

End point description:

Local reactions included pain at injection site, redness and swelling. Redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit =0.5 cm. Pain at injection site was graded as mild: hurts if gently touched; moderate: hurts if gently touched with crying; severe: limited limb movement. Redness and swelling were graded as mild: >0.0 to 2.0 cm; moderate >2.0 to 7.0 cm; and severe: >7.0 cm. Safety population included all the subjects who received at least 1 dose of the investigational product with safety follow up after any dose. Here, 'Number of Subjects Analysed' = number of subjects with any e-diary data reported after Dose 3.

| End point type | Primary |
|---|---|

End point timeframe:

Within 7 Days after Dose 3

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive data was planned to be analysed for this endpoint.

| End point values | 20vPnC | 13vPnC | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 940 | 477 | | |
| Units: Percentage of subjects | | | | |
| number (confidence interval 95%) | | | | |
| Redness: Mild | 19.4 (16.9 to 22.0) | 17.0 (13.7 to 20.7) | | |
| Redness: Moderate | 3.8 (2.7 to 5.3) | 3.1 (1.8 to 5.1) | | |
| Redness: Severe | 0 (0.0 to 0.4) | 0.2 (0.0 to 1.2) | | |
| Swelling: Mild | 12.2 (10.2 to 14.5) | 13.0 (10.1 to 16.4) | | |
| Swelling: Moderate | 4.1 (3.0 to 5.6) | 3.1 (1.8 to 5.1) | | |
| Swelling: Severe | 0 (0.0 to 0.4) | 0.2 (0.0 to 1.2) | | |
| Pain at the injection site: Mild | 16.3 (14.0 to 18.8) | 16.6 (13.3 to 20.2) | | |
| Pain at the injection site: Moderate | 8.3 (6.6 to 10.2) | 10.3 (7.7 to 13.4) | | |
| Pain at the injection site: Severe | 0.1 (0.0 to 0.6) | 0 (0.0 to 0.8) | | |

### Statistical analyses

No statistical analyses for this end point

## Primary: Percentage of Subjects With Local Reactions Within 7 Days After Dose 4

| End point title | Percentage of Subjects With Local Reactions Within 7 Days After Dose 4[4] |
|---|---|

End point description:

Local reactions included pain at injection site, redness and swelling. Redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit =0.5 cm. Pain at injection site was graded as mild: hurts if gently touched; moderate: hurts if gently touched with crying; severe: limited limb movement. Redness and swelling were graded as mild: >0.0 to 2.0 cm; moderate >2.0 to 7.0 cm; and severe: >7.0 cm. Safety population included all the subjects who received at least 1 dose of the investigational product with safety follow up after any dose. Here, 'Number of Subjects Analysed' = number of subjects with any e-diary data reported after Dose 4.

| End point type | Primary |
|---|---|

End point timeframe:

Within 7 Days after Dose 4

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive data was planned to be analysed for this endpoint.

| **End point values** | 20vPnC | 13vPnC | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 892 | 454 | | |
| Units: Percentage of subjects | | | | |
| number (confidence interval 95%) | | | | |
| Redness: Mild | 15.1 (12.8 to 17.7) | 19.4 (15.8 to 23.3) | | |
| Redness: Moderate | 5.9 (4.5 to 7.7) | 2.4 (1.2 to 4.3) | | |
| Redness: Severe | 0.1 (0.0 to 0.6) | 0 (0.0 to 0.8) | | |
| Swelling: Mild | 10.1 (8.2 to 12.3) | 11.5 (8.7 to 14.7) | | |
| Swelling: Moderate | 4.7 (3.4 to 6.3) | 2.9 (1.5 to 4.8) | | |
| Swelling: Severe | 0 (0.0 to 0.4) | 0 (0.0 to 0.8) | | |
| Pain at the injection site: Mild | 19.8 (17.3 to 22.6) | 21.8 (18.1 to 25.9) | | |
| Pain at the injection site: Moderate | 10.2 (8.3 to 12.4) | 10.1 (7.5 to 13.3) | | |
| Pain at the injection site: Severe | 0.8 (0.3 to 1.6) | 0 (0.0 to 0.8) | | |

### Statistical analyses

No statistical analyses for this end point

## Primary: Percentage of Subjects With Systemic Events Within 7 Days After Dose 1

| End point title | Percentage of Subjects With Systemic Events Within 7 Days After Dose 1[5] |
|---|---|

End point description:

Systemic events included fever, decreased appetite, drowsiness, and irritability. Fever was defined as an axillary temperature greater than or equal to (>=)38.0 degree Celsius (C), and categorised as >=38.0 to 38.4 degree C, >38.4 to 38.9 degree C,>38.9 to 40.0 degree C and >40.0 degree C; decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed); drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity); Irritability: graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). Safety population included all the subjects who received at least 1 dose of the IP with safety follow up after any dose. 'Number of Subjects Analysed' = number of subjects with any e-diary data reported after Dose 1.

| End point type | Primary |
|---|---|

End point timeframe:

Within 7 Days after Dose 1

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive data was planned to be analysed for this endpoint.

| End point values | 20vPnC | 13vPnC | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 992 | 498 | | |
| Units: Percentage of subjects | | | | |
| number (confidence interval 95%) | | | | |
| Fever: >=38.0 degree C | 9.3 (7.5 to 11.3) | 9.8 (7.4 to 12.8) | | |
| Fever: >=38.0 degree C to 38.4 degree C | 6.3 (4.8 to 7.9) | 7.8 (5.6 to 10.6) | | |
| Fever: >38.4 degree C to 38.9 degree C | 2.3 (1.5 to 3.5) | 1.8 (0.8 to 3.4) | | |
| Fever: >38.9 degree C to 40.0 degree C | 0.7 (0.3 to 1.4) | 0.2 (0.0 to 1.1) | | |
| Fever: >40.0 degree C | 0 (0.0 to 0.4) | 0 (0.0 to 0.7) | | |
| Decreased appetite: Mild | 14.2 (12.1 to 16.5) | 14.7 (11.7 to 18.1) | | |
| Decreased appetite: Moderate | 10.3 (8.5 to 12.3) | 8.6 (6.3 to 11.5) | | |
| Decreased appetite: Severe | 0.5 (0.2 to 1.2) | 0.4 (0.0 to 1.4) | | |
| Drowsiness: Mild | 48.5 (45.3 to 51.6) | 47.4 (42.9 to 51.9) | | |
| Drowsiness: Moderate | 15.8 (13.6 to 18.2) | 14.5 (11.5 to 17.9) | | |
| Drowsiness: Severe | 0.5 (0.2 to 1.2) | 0.4 (0.0 to 1.4) | | |
| Irritability: Mild | 22.7 (20.1 to 25.4) | 22.9 (19.3 to 26.8) | | |
| Irritability: Moderate | 41.2 (38.1 to 44.4) | 41.4 (37.0 to 45.8) | | |
| Irritability: Severe | 4.3 (3.2 to 5.8) | 4.2 (2.6 to 6.4) | | |

### Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Subjects With Systemic Events Within 7 Days After Dose 2

| End point title | Percentage of Subjects With Systemic Events Within 7 Days After Dose 2[6] |
|---|---|

End point description:

Systemic events included fever, decreased appetite, drowsiness and irritability. Fever was defined as an axillary temperature >=38.0 degree C, and categorised as >=38.0 to 38.4 degree C, >38.4 to 38.9 degree C,>38.9 to 40.0 degree C and >40.0 degree C; decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed); drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity); Irritability: graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). Safety population included all the subjects who received at least 1 dose of the IP with safety follow up after any dose. 'Number of Subjects Analysed' = number of subjects with any e-diary data reported after Dose 2.

| End point type | Primary |
|---|---|

End point timeframe:

Within 7 Days after Dose 2

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive data was planned to be analysed for this endpoint.

| End point values | 20vPnC | 13vPnC | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 952 | 485 | | |
| Units: Percentage of subjects | | | | |
| number (confidence interval 95%) | | | | |
| Fever: >=38.0 degree C | 15.5 (13.3 to 18.0) | 11.3 (8.7 to 14.5) | | |
| Fever: >=38.0 degree C to 38.4 degree C | 10.6 (8.7 to 12.7) | 8.5 (6.1 to 11.3) | | |
| Fever: >38.4 degree C to 38.9 degree C | 3.6 (2.5 to 5.0) | 2.7 (1.4 to 4.5) | | |
| Fever: >38.9 degree C to 40.0 degree C | 1.4 (0.7 to 2.3) | 0.2 (0.0 to 1.1) | | |
| Fever: >40.0 degree C | 0 (0.0 to 0.4) | 0 (0.0 to 0.8) | | |
| Decreased appetite: Mild | 13.4 (11.3 to 15.8) | 12.0 (9.2 to 15.2) | | |
| Decreased appetite: Moderate | 9.6 (7.8 to 11.6) | 8.2 (6.0 to 11.1) | | |
| Decreased appetite: Severe | 0.7 (0.3 to 1.5) | 0.4 (0.0 to 1.5) | | |
| Drowsiness: Mild | 35.3 (32.3 to 38.4) | 35.3 (31.0 to 39.7) | | |
| Drowsiness: Moderate | 13.4 (11.3 to 15.8) | 13.8 (10.9 to 17.2) | | |
| Drowsiness: Severe | 0.4 (0.1 to 1.1) | 1.2 (0.5 to 2.7) | | |
| Irritability: Mild | 23.2 (20.6 to 26.0) | 19.8 (16.3 to 23.6) | | |
| Irritability: Moderate | 37.3 (34.2 to 40.4) | 42.7 (38.2 to 47.2) | | |
| Irritability: Severe | 4.2 (3.0 to 5.7) | 5.2 (3.4 to 7.5) | | |

### Statistical analyses

No statistical analyses for this end point

## Primary: Percentage of Subjects With Systemic Events Within 7 Days After Dose 3

| End point title | Percentage of Subjects With Systemic Events Within 7 Days After Dose 3[7] |
|---|---|

End point description:

Systemic events included fever, decreased appetite, drowsiness and irritability. Fever was defined as an axillary temperature >=38.0 degree C, and categorised as >=38.0 to 38.4 degree C, >38.4 to 38.9 degree C,>38.9 to 40.0 degree C and >40.0 degree C; decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed); drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity); Irritability: graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). Safety population included all the subjects who received at least 1 dose of the IP with safety follow up after any dose. 'Number of Subjects Analysed' = number of subjects with any e-diary data reported after Dose 3.

| End point type | Primary |
|---|---|

End point timeframe:

Within 7 Days after Dose 3

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive data was planned to be analysed for this endpoint.

| End point values | 20vPnC | 13vPnC | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 940 | 477 | | |
| Units: Percentage of subjects | | | | |
| number (confidence interval 95%) | | | | |
| Fever: >=38.0 degree C | 11.6 (9.6 to 13.8) | 9.9 (7.3 to 12.9) | | |
| Fever: >=38.0 degree C to 38.4 degree C | 7.4 (5.9 to 9.3) | 8.2 (5.9 to 11.0) | | |
| Fever: >38.4 degree C to 38.9 degree C | 2.9 (1.9 to 4.2) | 0.6 (0.1 to 1.8) | | |
| Fever: >38.9 degree C to 40.0 degree C | 1.3 (0.7 to 2.2) | 1.0 (0.3 to 2.4) | | |
| Fever: >40.0 degree C | 0 (0.0 to 0.4) | 0 (0.0 to 0.8) | | |
| Decreased appetite: Mild | 15.0 (12.8 to 17.4) | 10.5 (7.9 to 13.6) | | |
| Decreased appetite: Moderate | 8.2 (6.5 to 10.1) | 6.3 (4.3 to 8.9) | | |
| Decreased appetite: Severe | 0.4 (0.1 to 1.1) | 0.4 (0.1 to 1.5) | | |
| Drowsiness: Mild | 26.6 (23.8 to 29.5) | 27.3 (23.3 to 31.5) | | |
| Drowsiness: Moderate | 8.5 (6.8 to 10.5) | 9.0 (6.6 to 12.0) | | |
| Drowsiness: Severe | 0.2 (0.0 to 0.8) | 0 (0.0 to 0.8) | | |
| Irritability: Mild | 22.3 (19.7 to 25.1) | 22.2 (18.6 to 26.2) | | |
| Irritability: Moderate | 30.1 (27.2 to 33.2) | 29.8 (25.7 to 34.1) | | |
| Irritability: Severe | 2.3 (1.5 to 3.5) | 2.7 (1.5 to 4.6) | | |

### Statistical analyses

No statistical analyses for this end point

## Primary: Percentage of Subjects With Systemic Events Within 7 Days After Dose 4

| End point title | Percentage of Subjects With Systemic Events Within 7 Days After Dose 4[8] |
|---|---|

End point description:

Systemic events included fever, decreased appetite, drowsiness and irritability. Fever was defined as an axillary temperature >=38.0 degree C, and categorised as >=38.0 to 38.4 degree C, >38.4 to 38.9 degree C, >38.9 to 40.0 degree C and >40.0 degree C; decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed); drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity); Irritability: graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). Safety population included all the subjects who received at least 1 dose of the IP with safety follow up after any dose. 'Number of Subjects Analysed' = number of subjects with any e-diary data reported after Dose 4.

| End point type | Primary |
|---|---|

End point timeframe:

Within 7 Days after Dose 4

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive data was planned to be analysed for this endpoint.

| End point values | 20vPnC | 13vPnC | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 892 | 454 | | |
| Units: Percentage of subjects | | | | |
| number (confidence interval 95%) | | | | |
| Fever: >=38.0 degree C | 18.0 (15.6 to 20.7) | 17.0 (13.6 to 20.7) | | |
| Fever: >=38.0 degree C to 38.4 degree C | 9.8 (7.9 to 11.9) | 9.5 (6.9 to 12.5) | | |
| Fever: >38.4 degree C to 38.9 degree C | 4.5 (3.2 to 6.1) | 4.2 (2.5 to 6.5) | | |
| Fever: >38.9 degree C to 40.0 degree C | 3.7 (2.6 to 5.2) | 3.1 (1.7 to 5.1) | | |
| Fever: >40.0 degree C | 0.1 (0.0 to 0.6) | 0.2 (0.0 to 1.2) | | |
| Decreased appetite: Mild | 16.1 (13.8 to 18.7) | 12.3 (9.5 to 15.7) | | |
| Decreased appetite: Moderate | 10.5 (8.6 to 12.7) | 11.7 (8.9 to 15.0) | | |
| Decreased appetite: Severe | 1.7 (0.9 to 2.8) | 1.8 (0.8 to 3.4) | | |
| Drowsiness: Mild | 24.2 (21.4 to 27.2) | 25.1 (21.2 to 29.4) | | |
| Drowsiness: Moderate | 12.2 (10.1 to 14.6) | 10.6 (7.9 to 13.8) | | |
| Drowsiness: Severe | 0.7 (0.2 to 1.5) | 0.2 (0.0 to 1.2) | | |
| Irritability: Mild | 21.4 (18.8 to 24.3) | 22.0 (18.3 to 26.1) | | |
| Irritability: Moderate | 31.4 (28.4 to 34.5) | 29.7 (25.6 to 34.2) | | |
| Irritability: Severe | 2.5 (1.6 to 3.7) | 3.3 (1.9 to 5.4) | | |

### Statistical analyses

No statistical analyses for this end point

## Primary: Percentage of Subjects With Adverse Events (AEs) From Dose 1 to 1 Month After Dose 3

| End point title | Percentage of Subjects With Adverse Events (AEs) From Dose 1 to 1 Month After Dose 3[9] |
|---|---|

End point description:

An adverse event (AE) was any untoward medical occurrence in a subject, temporally associated with the use of study vaccine, whether or not considered related to the study vaccine. Safety population included all the subjects who received at least 1 dose of the IP with safety follow up after any dose.

| End point type | Primary |
|---|---|

End point timeframe:

From Day 1 of Dose 1 to 1 Month after Dose 3

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive data was planned to be analysed for this endpoint.

| End point values | 20vPnC | 13vPnC | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 1000 | 503 | | |
| Units: Percentage of subjects | | | | |
| number (confidence interval 95%) | 29.6 (26.8 to 32.5) | 27.6 (23.8 to 31.8) | | |

### Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Subjects With AEs From Dose 4 to 1 Month After Dose 4

| End point title | Percentage of Subjects With AEs From Dose 4 to 1 Month After Dose 4[10] |
|---|---|

End point description:

An AE was any untoward medical occurrence in a subject, temporally associated with the use of study vaccine, whether or not considered related to the study vaccine. Safety population included all the subjects who received at least 1 dose of the IP with safety follow up after any dose. Here, 'Number of Subjects Analysed' = number of subjects who received Dose 4.

| End point type | Primary |
|---|---|

End point timeframe:

From Dose 4 to 1 Month after Dose 4

Notes:

[10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive data was planned to be analysed for this endpoint.

| End point values | 20vPnC | 13vPnC | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 923 | 461 | | |
| Units: Percentage of subjects | | | | |
| number (confidence interval 95%) | 15.1 (12.8 to 17.5) | 15.8 (12.6 to 19.5) | | |

### Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Subjects With Serious Adverse Events (SAEs) From Dose 1 to 6 Months After Dose 4

| End point title | Percentage of Subjects With Serious Adverse Events (SAEs) From Dose 1 to 6 Months After Dose 4[11] |
|---|---|

End point description:

A SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalisation or prolongation of existing hospitalisation; was life-threatening; resulted in persistent or significant disability/incapacity; congenital anomaly/birth defect and other important medical events. Safety population included all the subjects who received at least 1 dose of the IP with safety follow up after any dose.

| End point type | Primary |
|---|---|

End point timeframe:

From Day 1 of Dose 1 to 6 Months after Dose 4

Notes:

[11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive data was planned to be analysed for this endpoint.

| **End point values** | 20vPnC | 13vPnC | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 1000 | 503 | | |
| Units: Percentage of subjects | | | | |
| number (confidence interval 95%) | 4.4 (3.2 to 5.9) | 5.6 (3.7 to 7.9) | | |

## Statistical analyses

No statistical analyses for this end point

## Primary: Percentage of Subjects With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Dose 1 to 6 Months After Dose 4

| End point title | Percentage of Subjects With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Dose 1 to 6 Months After Dose 4[12] |
|---|---|

End point description:

An NDCMC was defined as a significant disease or medical condition, not previously identified, that is expected to be persistent or was otherwise long-lasting in its effects. Safety population included all the subjects who received at least 1 dose of the IP with safety follow up after any dose.

| End point type | Primary |
|---|---|

End point timeframe:

From Day 1 of Dose 1 to 6 Months after Dose 4

Notes:

[12] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive data was planned to be analysed for this endpoint.

| **End point values** | 20vPnC | 13vPnC | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 1000 | 503 | | |
| Units: Percentage of subjects | | | | |
| number (confidence interval 95%) | 2.8 (1.9 to 4.0) | 2.8 (1.5 to 4.6) | | |

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Local reactions/systemic events:[systematic assessment (SA)]: Within 7 days after Dose 1, 2, 3, 4; Non-SA: SAEs: Day 1 up to 6 months after Dose4, other AEs(NSAEs): Day 1 of Dose1 up to 1 month after Dose3 and from Day 1 of Dose4 up to 1 month after Dose4

Adverse event reporting additional description:

The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as non-serious in another subject, or one subject may have experienced both a serious and non-serious event during the study.

| | |
|---|---|
| Assessment type | Non-systematic |

### Dictionary used

| | |
|---|---|
| Dictionary name | MedDRA |
| Dictionary version | 25.0 |

### Reporting groups

| | |
|---|---|
| Reporting group title | 13vPnC |

Reporting group description:

Infants 42 to 98 days of age were enrolled to receive 4 doses of 0.5 mL 13vPnC intramuscularly. The first dose was given at Day 1, with the second and third doses given at 42-63 day intervals. Dose 4 was administered between 12 to 15 months of age. Subjects were followed up to 6 months after last dose.

| | |
|---|---|
| Reporting group title | 20vPnC |

Reporting group description:

Infants 42 to 98 days of age were enrolled to receive 4 doses of 0.5 mL 20vPnC intramuscularly. The first dose was given at Day 1, with the second and third doses given at 42-63 day intervals. Dose 4 was administered between 12 to 15 months of age. Subjects were followed up to 6 months after last dose.

| Serious adverse events | 13vPnC | 20vPnC | |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 28 / 503 (5.57%) | 44 / 1000 (4.40%) | |
| number of deaths (all causes) | 0 | 0 | |
| number of deaths resulting from adverse events | 0 | 0 | |
| Injury, poisoning and procedural complications | | | |
| Skull fracture | | | |
| subjects affected / exposed | 1 / 503 (0.20%) | 0 / 1000 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Humerus fracture | | | |
| subjects affected / exposed | 0 / 503 (0.00%) | 1 / 1000 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Foreign body aspiration | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 503 (0.00%) | 1 / 1000 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Concussion | | | |
| subjects affected / exposed | 0 / 503 (0.00%) | 1 / 1000 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Thermal burn | | | |
| subjects affected / exposed | 0 / 503 (0.00%) | 1 / 1000 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nervous system disorders | | | |
| Cerebral haemorrhage | | | |
| subjects affected / exposed | 0 / 503 (0.00%) | 1 / 1000 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Febrile convulsion | | | |
| subjects affected / exposed | 0 / 503 (0.00%) | 1 / 1000 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infantile spasms | | | |
| subjects affected / exposed | 0 / 503 (0.00%) | 1 / 1000 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Partial seizures | | | |
| subjects affected / exposed | 0 / 503 (0.00%) | 1 / 1000 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Seizure | | | |
| subjects affected / exposed | 1 / 503 (0.20%) | 0 / 1000 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood and lymphatic system disorders | | | |

| | | | |
|---|---|---|---|
| Anaemia | | | |
| subjects affected / exposed | 1 / 503 (0.20%) | 0 / 1000 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lymphadenopathy | | | |
| subjects affected / exposed | 0 / 503 (0.00%) | 1 / 1000 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| General disorders and administration site conditions | | | |
| Adverse food reaction | | | |
| subjects affected / exposed | 0 / 503 (0.00%) | 1 / 1000 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pyrexia | | | |
| subjects affected / exposed | 3 / 503 (0.60%) | 1 / 1000 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Immune system disorders | | | |
| Anaphylactic reaction | | | |
| subjects affected / exposed | 0 / 503 (0.00%) | 1 / 1000 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal disorders | | | |
| Allergic colitis | | | |
| subjects affected / exposed | 1 / 503 (0.20%) | 0 / 1000 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Enteritis | | | |
| subjects affected / exposed | 0 / 503 (0.00%) | 1 / 1000 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intestinal haemorrhage | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 503 (0.00%) | 1 / 1000 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intussusception | | | |
| subjects affected / exposed | 1 / 503 (0.20%) | 0 / 1000 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Bronchospasm | | | |
| subjects affected / exposed | 1 / 503 (0.20%) | 1 / 1000 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Acute respiratory failure | | | |
| subjects affected / exposed | 1 / 503 (0.20%) | 0 / 1000 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Skin and subcutaneous tissue disorders | | | |
| Hypersensitivity vasculitis | | | |
| subjects affected / exposed | 0 / 503 (0.00%) | 1 / 1000 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urticaria | | | |
| subjects affected / exposed | 0 / 503 (0.00%) | 1 / 1000 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Psychiatric disorders | | | |
| Breath holding | | | |
| subjects affected / exposed | 0 / 503 (0.00%) | 1 / 1000 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infections and infestations | | | |
| Abscess | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 503 (0.00%) | 1 / 1000 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Adenovirus infection | | | |
| subjects affected / exposed | 0 / 503 (0.00%) | 2 / 1000 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bronchiolitis | | | |
| subjects affected / exposed | 5 / 503 (0.99%) | 5 / 1000 (0.50%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Arthritis bacterial | | | |
| subjects affected / exposed | 1 / 503 (0.20%) | 0 / 1000 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Escherichia urinary tract infection | | | |
| subjects affected / exposed | 1 / 503 (0.20%) | 1 / 1000 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Croup infectious | | | |
| subjects affected / exposed | 1 / 503 (0.20%) | 0 / 1000 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| COVID-19 | | | |
| subjects affected / exposed | 1 / 503 (0.20%) | 1 / 1000 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bronchitis | | | |
| subjects affected / exposed | 1 / 503 (0.20%) | 1 / 1000 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastroenteritis salmonella | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 503 (0.20%) | 1 / 1000 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastroenteritis viral | | | |
| subjects affected / exposed | 0 / 503 (0.00%) | 1 / 1000 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastroenteritis norovirus | | | |
| subjects affected / exposed | 0 / 503 (0.00%) | 1 / 1000 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Laryngitis | | | |
| subjects affected / exposed | 0 / 503 (0.00%) | 1 / 1000 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastroenteritis | | | |
| subjects affected / exposed | 2 / 503 (0.40%) | 3 / 1000 (0.30%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Otitis media acute | | | |
| subjects affected / exposed | 2 / 503 (0.40%) | 1 / 1000 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Meningitis viral | | | |
| subjects affected / exposed | 1 / 503 (0.20%) | 0 / 1000 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pharyngotonsillitis | | | |
| subjects affected / exposed | 0 / 503 (0.00%) | 1 / 1000 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory syncytial virus bronchiolitis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 503 (0.00%) | 1 / 1000 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pyelonephritis acute | | | |
| subjects affected / exposed | 0 / 503 (0.00%) | 1 / 1000 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 503 (0.00%) | 2 / 1000 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Viraemia | | | |
| subjects affected / exposed | 1 / 503 (0.20%) | 0 / 1000 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urinary tract infection bacterial | | | |
| subjects affected / exposed | 1 / 503 (0.20%) | 0 / 1000 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urinary tract infection | | | |
| subjects affected / exposed | 2 / 503 (0.40%) | 1 / 1000 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory syncytial virus infection | | | |
| subjects affected / exposed | 0 / 503 (0.00%) | 2 / 1000 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory syncytial virus bronchitis | | | |
| subjects affected / exposed | 0 / 503 (0.00%) | 1 / 1000 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Viral infection | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 503 (0.20%) | 0 / 1000 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 0 / 503 (0.00%) | 1 / 1000 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 5 %

| **Non-serious adverse events** | 13vPnC | 20vPnC | |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 481 / 503 (95.63%) | 960 / 1000 (96.00%) | |
| Nervous system disorders | | | |
| Hypersomnia (INCREASED SLEEP) | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 389 / 503 (77.34%) | 809 / 1000 (80.90%) | |
| occurrences (all) | 1069 | 2104 | |
| General disorders and administration site conditions | | | |
| Injection site erythema (REDNESS) | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 224 / 503 (44.53%) | 455 / 1000 (45.50%) | |
| occurrences (all) | 423 | 875 | |
| Injection site pain (PAIN) | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 309 / 503 (61.43%) | 609 / 1000 (60.90%) | |
| occurrences (all) | 663 | 1253 | |
| Injection site swelling (SWELLING) | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 176 / 503 (34.99%) | 372 / 1000 (37.20%) | |
| occurrences (all) | 344 | 704 | |
| Pyrexia (FEVER) | | | |
| alternative assessment type: | | | |

| | | | |
|---|---|---|---|
| Systematic | | | |
| subjects affected / exposed | 159 / 503 (31.61%) | 336 / 1000 (33.60%) | |
| occurrences (all) | 245 | 550 | |
| Psychiatric disorders | | | |
| Irritability (IRRITABILITY) | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 432 / 503 (85.88%) | 883 / 1000 (88.30%) | |
| occurrences (all) | 1556 | 3018 | |
| Infections and infestations | | | |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 28 / 503 (5.57%) | 59 / 1000 (5.90%) | |
| occurrences (all) | 30 | 67 | |
| Metabolism and nutrition disorders | | | |
| Decreased appetite (DECREASED APPETITE) | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 249 / 503 (49.50%) | 549 / 1000 (54.90%) | |
| occurrences (all) | 487 | 1117 | |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported